An open-label, multicenter, phase II study of LDK378 in patients with non-small cell lung cancer harboring ROS1 rearrangement
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 09 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated